Literature DB >> 2153011

Effect of preoperative chemotherapy on mastectomy for locally advanced breast cancer.

D N Danforth1, M E Lippman, H McDonald, J Bader, E Egan, M Lampert, S M Steinberg, S M Swain.   

Abstract

Mastectomy is frequently performed after intensive chemotherapy for locally advanced breast cancer. The effects of preoperative chemotherapy on the postoperative course and the timing of subsequent adjuvant therapy, however, have not been defined. We therefore reviewed the perioperative course of 54 patients undergoing mastectomy after combination (CAMFPT) chemotherapy for stage IIIA,B (IIIA - 25 pts; IIIB noninflammatory - 5 pts; IIIB inflammatory-24 patients) breast cancer. A median of 7 cycles (6 months) of chemotherapy was administered preoperatively. Mastectomy was performed a median of 20 days after last chemotherapy; white blood cell count (WBC) and platelet counts returned to normal limits preoperatively. Total mastectomy with or without axillary node dissection was performed in 53 patients, and a Halsted radical mastectomy in 1 patient. Negative margins on breast and/or axillary tissue were achieved in 47 patients (87.0%). Postoperative complications included skin flap necrosis in 8 patients (14.8%), seroma formation in 5 patients (9.3%), and wound infection in 1 patient (1.9%). Median operative blood loss (550 cc), hospital stay (8 days), and duration of wound catheter drainage (6 days) were comparable to published reports for modified radical mastectomy without preoperative chemotherapy. Systemic chemotherapy was resumed a median of 16 days after mastectomy, and radiotherapy started a median of 33 days after mastectomy. These findings indicate that intensive preoperative chemotherapy does not increase the hospital course or the postoperative complications of mastectomy for locally advanced breast cancer. In view of the current interest in treatment of stage I and II breast cancer with preoperative chemotherapy, this information may be useful in their management as well.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2153011

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  8 in total

Review 1.  Management of locally advanced breast cancer.

Authors:  P I Borgen
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

2.  The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India.

Authors:  Umesh Das; K C Lakshmaiah; K Govind Babu; T M Suresh; D Lokanatha; Linu Jacob; Suresh Babu
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-04       Impact factor: 4.553

3.  Determining the use of prophylactic antibiotics in breast cancer surgeries: a survey of practice.

Authors:  Sergio A Acuna; Fernando A Angarita; Jaime Escallon; Mauricio Tawil; Lilian Torregrosa
Journal:  BMC Surg       Date:  2012-08-31       Impact factor: 2.102

4.  Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice.

Authors:  Domenico Angelucci; Nicola Tinari; Antonino Grassadonia; Ettore Cianchetti; Giampiero Ausili-Cefaro; Laura Iezzi; Marinella Zilli; Simona Grossi; Lucia Anna Ursini; Maria Teresa Scognamiglio; Graziella Castrilli; Michele De Tursi; Paolo Noccioli; Pasquale Cioffi; Stefano Iacobelli; Clara Natoli
Journal:  J Cancer Res Clin Oncol       Date:  2012-10-10       Impact factor: 4.553

Review 5.  Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: a systematic review.

Authors:  Antonino Grassadonia; Marta Caporale; Nicola Tinari; Marinella Zilli; Michele DeTursi; Teresa Gamucci; Patrizia Vici; Clara Natoli
Journal:  J Cancer       Date:  2015-05-12       Impact factor: 4.207

6.  A study of triple negative breast cancer at a tertiary cancer care center in southern India.

Authors:  K C Lakshmaiah; U Das; T M Suresh; D Lokanatha; G K Babu; L A Jacob; S Babu
Journal:  Ann Med Health Sci Res       Date:  2014-11

7.  Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy.

Authors:  Roberto J Arai; Vanessa Petry; Paulo M Hoff; Max S Mano
Journal:  Biomark Res       Date:  2018-06-14

8.  Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2- locally advanced breast cancer.

Authors:  V Petry; D M Gagliato; A I C Leal; R J Arai; E Longo; F Andrade; M D Ricci; J R Piato; R Barroso-Sousa; P M Hoff; M S Mano
Journal:  Braz J Med Biol Res       Date:  2015-03-06       Impact factor: 2.590

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.